The updated findings from the ALTERNATIVE Phase III trial demonstrated that in postmenopausal women with HR-positive/HER2-positive advanced breast cancer, the combination of aromatase inhibitors (AIs) with lapatinib significantly extended the median progression-free survival (mPFS) compared to that of patients receiving AI monotherapy (11 vs. 5.6 months, P = 0.0063) [54]. The gene discussed is ERBB2; the disease is breast carcinoma.